newschorioretinal atrophyretinal gene therapy
Long-Term Safety and Ophthalmic Outcomes of Voretigene Neparvovec-rzyl in US Clinical Practice: Interim Multicenter Observational Findings
By MedXY|Aug 18, 2026
Interim real-world data over nearly 4 years confirms the long-term safety and sustained visual benefits of voretigene neparvovec-rzyl in treating inherited retinal dystrophies, with manageable procedure-related adverse events including chor